Mumford, A D & Gibbison, B J J 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 Dimitriadis, G K 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 RECOVERY Collaborative Group & Dark, P 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet . https://doi.org/10.1016/S0140-6736(22)01109-6
Lancet (London, England) LANCET RECOVERY Collaborative Group 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) a randomised controlled, open-label, platform trial ', The Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Mumford, A D 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised controlled, open-label, platform trial ', Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Group, RECOVERY C & Dark, P 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. ', Lancet (London, England), vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7
RECOVERY Collaborative Group & Downey, D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', The Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Mumford, A D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Lancet (London, England) Group, RECOVERY C, Felton, T, Dark, P & Mathioudakis, A 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5
Lancet (London, England) investigators, ISARICC & Dark, P 2021, ' Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. ', Lancet (London, England), vol. 398, no. 10296, pp. 223-237 . https://doi.org/10.1016/S0140-6736(21)00799-6 The Lancet The Lancet, Elsevier, 2021, 398 (10296), pp.223-237. ⟨10.1016/S0140-6736(21)00799-6⟩ Drake, T, Riad, A M, Fairfield, C J, Egan, C, Knight, S, Pius, R, Hardwick, H E, Norman, L, Shaw, K, Mclean, K, Docherty, A B & Harrison, E M 2021, ' Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK : A prospective, multicentre cohort study ', The Lancet, vol. 398, no. 10296 . https://doi.org/10.1016/S0140-6736(21)00799-6
2021, ' Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study : a multicentre, prospective cohort study ', The Lancet Microbe . https://doi.org/10.1016/S2666-5247(21)00090-2 LANCET MICROBE The Lancet Microbe E365 E354 investigators, ISARICC & Dark, P 2021, ' Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. ', The Lancet. Microbe, vol. 2, no. 8, pp. e354-e365 . https://doi.org/10.1016/S2666-5247(21)00090-2 The Lancet. Microbe
Investigators, ISARICC & Dark, P 2021, ' Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. ', The Lancet. Respiratory medicine, vol. 9, no. 7, pp. 773-785 . https://doi.org/10.1016/S2213-2600(21)00175-2 2021, ' Changes in in-hospital mortality in the first wave of COVID-19 : a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK ', The Lancet Respiratory Medicine . https://doi.org/10.1016/S2213-2600(21)00175-2 The Lancet. Respiratory Medicine
LANCET RESPIRATORY MEDICINE The Lancet. Respiratory Medicine ISARIC4C Investigators 2021, ' Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK ', The Lancet. Respiratory medicine, vol. 9, no. 7, pp. 699-711 . https://doi.org/10.1016/S2213-2600(21)00013-8 2021, ' Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19 : a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK ', The Lancet Respiratory Medicine, vol. 9, no. 7, pp. 699-711 . https://doi.org/10.1016/S2213-2600(21)00013-8